Generic drug of Torental LP
Therapeutic class: Cardiology and angiology
active ingredients: Pentoxifylline
laboratory: Teva Sante
Extended release film-coated tablet
Box of 30
· Symptomatic treatment of intermittent claudication of chronic obliterative peripheral arterial disease (stage 2).
NB: this indication is based on double-blind clinical trials compared to placebo which show an increase of the perimeter of walking of at least 50% in 50 to 60% of treated patients against 20 to 40% of patients following only rules diet and lifestyle.
· Adjunctive treatment for symptomatic chronic cognitive and neuro-sensory pathological deficit in the elderly (excluding Alzheimer's disease and other dementias).
Dosage PENTOXIFYLLINE LP TEVA 400 mg Extended-release film-coated tablet Box of 30
1 to 3 tablets daily, possibly in 2 unequal doses, preferably during the meal or meals.
In patients with renal impairment, do not exceed 2 tablets daily. In case of severe renal insufficiency, the dose should be reduced and adapted according to individual tolerance.
Due to the prolonged release process, the tablet membrane can exceptionally be found in the stool.
The tablet should be swallowed whole (without grinding, breaking or chewing) with a little water.
This medicine MUST NEVER BE USED in the following cases:
Hypersensitivity to pentoxifylline or any of the excipients of the tablet,
· Acute phase of myocardial infarction,
· Ongoing hemorrhage or major bleeding risk.
This medication is NOT recommended during pregnancy and lactation (see section Pregnancy and breast-feeding ).
Adverse effects Pentoxifylline LP Teva
· Digestive side effects such as: transient nausea, vomiting, gastralgia or diarrhea can be observed.
· Rarely hot flushes, arterial hypotension, headache, dizziness, insomnia, tachycardia, agitation may occur.
· Skin reactions (rash, urticaria, pruritus) are exceptionally observed, and isolated cases of anaphylactoid reactions with shock, angioedema and bronchospasm have been reported. At the first sign of such hypersensitivity reactions, treatment should be discontinued and appropriate therapeutic measures taken.
· There have been reports of haemorrhage and / or decreased prothrombin levels in pentoxifylline-treated patients with haemorrhagic risk factors (recent surgery, peptic ulcer) or anticoagulants or antiplatelet agents.
· Thrombocytopenia, cholestasis, or increased aminotransferase activity have been reported rarely.
· Exceptionally cases of aseptic meningitis have been reported, particularly in patients treated for systemic disease (lupus, rheumatoid arthritis ...). It is necessary to stop the treatment.